The final purchase price allocation for the acquisition of Boehringer Ingelheim’s CHC business is as follows (in € million):
| (€ million) |
Fair value at acquisition date |
|||
| Property, plant and equipment | 67 | |||
| Other intangible assets | 3,771 | |||
| Other non-current assets and liabilities | (84) | |||
| Inventories | 296 | |||
| Other current assets and liabilities | 46 | |||
| Held-for-sale assets | 77 | |||
| Net deferred tax position | (156) | |||
| Net assets of Boehringer Ingelheim’s CHC business as of January 1, 2017 | 4,017 | |||
| Goodwill | 2,222 | |||
| Purchase price | 6,239 | |||